ANDA 91626, held by Sun Pharmaceutical Industries. Epinastine Hydrochloride.
As of Nov 21, 2026, ANDA 91626 (Epinastine Hydrochloride), held by Sun Pharmaceutical Industries, was first approved by FDA on Oct 31, 2011, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Epinastine Hydrochloride0.05% · solution/drops;ophthalmic | Epinastine Hydrochloride | Discontinued |
| Jan 21, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 31, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters